Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Adc Therapeutics Sa (ADCT)

Adc Therapeutics Sa (ADCT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 483,120
  • Shares Outstanding, K 123,877
  • Annual Sales, $ 70,840 K
  • Annual Income, $ -157,850 K
  • EBIT $ -136 M
  • EBITDA $ -133 M
  • 60-Month Beta 1.93
  • Price/Sales 6.00
  • Price/Cash Flow N/A
  • Price/Book N/A

Options Overview Details

View History
  • Implied Volatility 850.05% (+34.95%)
  • Historical Volatility 51.49%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 850.05% on 02/11/26
  • IV Low 45.01% on 01/21/26
  • Expected Move (DTE 9) 0.05 (1.30%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 100
  • Volume Avg (30-Day) 43
  • Put/Call OI Ratio 0.05
  • Today's Open Interest 1,483
  • Open Int (30-Day) 1,761
  • Expected Range 3.87 to 3.97

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.32
  • Number of Estimates 1
  • High Estimate -0.32
  • Low Estimate -0.32
  • Prior Year -0.29
  • Growth Rate Est. (year over year) -10.34%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.25 +20.62%
on 01/28/26
4.20 -6.56%
on 02/06/26
+0.26 (+7.10%)
since 01/09/26
3-Month
2.94 +33.33%
on 12/03/25
4.62 -15.15%
on 12/02/25
-0.05 (-1.26%)
since 11/11/25
52-Week
1.05 +273.33%
on 04/09/25
4.80 -18.33%
on 10/30/25
+2.53 (+182.01%)
since 02/11/25

Most Recent Stories

More News
ADC Therapeutics Makes Grants to New Employees Under Inducement Plan

LAUSANNE, Switzerland , Feb. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 3.92 (+0.51%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

NEW YORK , Jan. 22, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are...

ADCT : 3.92 (+0.51%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors...

ADCT : 3.92 (+0.51%)
ADC Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Revenue and Cash Estimates and Recent Corporate Updates

Preliminary unaudited fourth quarter and full year 2025 net product revenue of approximately $22M and $73M respectively; cash and cash equivalents of approximately $261M as of December 31, 2025, provide...

ADCT : 3.92 (+0.51%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are...

ADCT : 3.92 (+0.51%)
ADC Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference

LAUSANNE, Switzerland , Jan. 8, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 3.92 (+0.51%)
ADC Therapeutics Announces New Employee Inducement Grant

LAUSANNE, Switzerland , Jan. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs), today announced...

ADCT : 3.92 (+0.51%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

NEW YORK , Jan. 1, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of  ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are...

ADCT : 3.92 (+0.51%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ADC Therapeutics SA - ADCT

NEW YORK , Dec. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ADC Therapeutics SA ("ADC Therapeutics" or the "Company") (NYSE: ADCT). Such investors are...

ADCT : 3.92 (+0.51%)
ADC Therapeutics Announces Updated Data from LOTIS-7 Phase 1b Clinical Trial of ZYNLONTA® in Combination with Bispecific Antibody Supporting Potential Best-in-Class Regimen in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma

ZYNLONTA® in combination with glofitamab (COLUMVI®) demonstrated an 89.8% ORR and 77.6% CR across the 49 efficacy-evaluable patients with a minimum of 6 months of follow-up

ADCT : 3.92 (+0.51%)

Business Summary

ADC Therapeutics SA is a late clinical-stage oncology-focused biotechnology company. It engages in development and commercialization of antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA is based in LAUSANNE, Switzerland.

See More

Key Turning Points

3rd Resistance Point 4.35
2nd Resistance Point 4.16
1st Resistance Point 4.04
Last Price 3.92
1st Support Level 3.73
2nd Support Level 3.54
3rd Support Level 3.42

See More

52-Week High 4.80
Last Price 3.92
Fibonacci 61.8% 3.37
Fibonacci 50% 2.93
Fibonacci 38.2% 2.48
52-Week Low 1.05

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar